Skip to main content
Fig. 1 | BMC Health Services Research

Fig. 1

From: Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity

Fig. 1

Markov model: Model structure represents the disease progression of rheumatoid arthritis patients with high disease activity measured by DAS28-ESR. DAS-28: Disease Activity Score with 28 joint counts, ESR: erythrocyte sedimentation rate

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us